ST宁科：部分董事及全体高管推出股份增持计划，彰显对公司前景信心
（证券代码：600165，证券简称：ST宁科）
核心内容摘要
- 公司部分董事及全体高级管理人员将首次集体增持股份，合计金额不低于370万元，不超过600万元。
- 增持计划显示管理层对公司未来发展前景及长期投资价值充满信心，旨在维护资本市场稳定，增强投资者信心。
- 本次增持主体此前均未直接持有公司股份，实施期为2026年7月28日至2027年1月27日，增持方式为二级市场集中竞价。
- 增持计划不设定价格区间，管理层承诺在增持期间及法定期限内不减持所增持股份。
- 公司警示相关政策及市场变化等风险因素可能影响增持计划推进。
详细解读
026年7月25日，宁夏中科生物科技股份有限公司（ST宁科）发布公告，披露部分董事及全体高管将实施公司股份增持计划。这一举措被认为是公司管理层对企业未来发展前景及长期投资价值高度认可的体现，亦有意向市场传递维稳信号，力求增强广大投资者的信心。
一、增持主体及其身份情况
本次参与增持的全部为公司董事及高管，包括董事长、总经理符杰，董事冯战胜，董事、副总经理兼董事会秘书王炜，副总经理李忠福、副总经理屈晓春，以及财务总监金相宇。值得注意的是，上述人员在本次公告前均未直接持有公司股份，且不存在一致行动人关系，进一步凸显本次增持的信号意义。
- 符杰：董事长、总经理
- 冯战胜：董事
- 王炜：董事、副总经理、董事会秘书
- 李忠福：副总经理
- 屈晓春：副总经理
- 金相宇：财务总监
二、增持计划具体安排
增持主体将自公告之日起6个月内，通过上海证券交易所集中竞价方式增持公司A股股份。合计增持金额为370万元至600万元，不设定价格区间与增持数量、比例区间。各自增持计划如下：
- 符杰：70-100万元
- 冯战胜：100-200万元
- 王炜：70-100万元
- 李忠福：70-100万元
- 屈晓春：30-50万元
- 金相宇：30-50万元
所有资金均为自有或自筹资金，增持主体承诺在增持期间及法定期限内不减持所持股份。
三、风险提示
公司提示，增持计划可能因政策或资本市场情况变化等不可预见因素延迟或无法实施。如出现上述风险情形，公司将及时履行信息披露义务。
四、对股东的影响与关注点
- 本次增持不会导致公司股权分布不符合上市条件，也不会导致控股股东或实际控制人变更。
- 公司将持续关注增持计划进展并按规定履行信息披露义务，提醒投资者注意风险。
- 管理层首次集体增持，表明对公司价值与前景的高度认可，或对市场信心及公司股价形成正面推动。
投资者需关注的敏感信息
- 高管首次集体增持，极大增强市场信心，或成为股价潜在催化剂。
- 增持计划实施期间长达半年，管理层承诺不减持，进一步稳定市场预期。
- 如市场环境或政策变化导致增持计划未能如期实施，可能对短期市场情绪产生波动。
公司声明
本次增持计划严格遵循《证券法》等相关法律法规，不会影响公司实际控制权。公司将持续履行信息披露义务，敬请投资者关注官方公告及风险提示。
免责声明： 本文仅为信息披露整理及分析，不构成任何投资建议。股市有风险，投资需谨慎。请投资者据此独立判断与决策。
ST Ningke: Board Members and Senior Executives Announce First-Ever Collective Share Purchase Plan, Signaling Strong Confidence in Company Outlook
(Stock Code: 600165, Stock Abbreviation: ST Ningke)
Key Highlights
- Several board members and all senior executives will collectively purchase company shares for the first time, with a combined investment of no less than RMB 3.7 million and up to RMB 6 million.
- This plan demonstrates management’s firm confidence in the company’s growth prospects and long-term value, aiming to stabilize the capital market and boost investor confidence.
- All participants currently hold no direct company shares; the purchase window is from July 28, 2026, to January 27, 2027, via centralized bidding on the Shanghai Stock Exchange.
- No preset price range for the share purchase; management commits not to sell any purchased shares during and after the plan, within legal timeframes.
- The company warns of potential risks—such as policy or market changes—that may affect the implementation of the plan.
Full Details
On July 25, 2026, Ningxia Zhongke Biotechnology Co., Ltd. (ST Ningke) announced that some directors and all senior management would implement a share purchase plan. This move is seen as a strong endorsement of the company’s future prospects and long-term investment value, sending a positive signal to the market and aiming to reinforce investor confidence.
1. Participants and Their Roles
All participants are board members and senior executives: Chairman & GM Fu Jie, Director Feng Zhansheng, Director/Deputy GM/Board Secretary Wang Wei, Deputy GMs Li Zhongfu and Qu Xiaochun, and CFO Jin Xiangyu. None of these individuals held company shares prior to this announcement, and there is no concerted action relationship among them, highlighting the significance of this share purchase.
- Fu Jie: Chairman & General Manager
- Feng Zhansheng: Director
- Wang Wei: Director, Deputy GM, Board Secretary
- Li Zhongfu: Deputy GM
- Qu Xiaochun: Deputy GM
- Jin Xiangyu: CFO
2. Details of the Share Purchase Plan
From the date of this announcement, participants will, within 6 months, purchase A-shares via centralized bidding on the Shanghai Stock Exchange. Total planned investment: RMB 3.7 million to 6 million, with no set price, quantity, or proportion. Individual plans are:
- Fu Jie: RMB 700,000–1,000,000
- Feng Zhansheng: RMB 1,000,000–2,000,000
- Wang Wei: RMB 700,000–1,000,000
- Li Zhongfu: RMB 700,000–1,000,000
- Qu Xiaochun: RMB 300,000–500,000
- Jin Xiangyu: RMB 300,000–500,000
All funds are either self-owned or self-raised. Participants promise not to sell any purchased shares during the purchase period or within legally required holding periods.
3. Risk Warning
The company notes that the plan may be delayed or become unfeasible due to policy or market changes or unforeseen factors. The company will promptly disclose if such risks arise.
4. Implications for Shareholders and Key Points
- This share purchase will not affect the company’s listing eligibility or result in a change of controlling shareholder or actual controller.
- The company will continue to update the market on the implementation of the plan and reminds investors of potential risks.
- This is the first time management has collectively increased their holdings, demonstrating their recognition of the company’s value and future, and could positively impact market sentiment and share price.
Price-Sensitive Information for Investors
- First-ever collective share purchase by senior management is a strong vote of confidence and may act as a catalyst for the share price.
- The long implementation window and commitment not to sell purchased shares further stabilize expectations.
- Any delays or inability to implement the plan due to policy or market changes could negatively affect short-term market sentiment.
Company Statement
This share purchase plan complies with the Securities Law and other relevant regulations and will not impact the company’s actual control. The company will continue to fulfill its information disclosure obligations. Investors are reminded to stay alert to official announcements and risk warnings.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The stock market carries risks, and investors should exercise caution and make independent decisions based on their own judgment.
